Immunotherapy Innovation Corvus Pharmaceuticals focuses on developing innovative immunotherapy drugs like mupadolimab and CPI06, providing an opportunity for collaboration with healthcare providers and institutions looking to offer cutting-edge cancer treatments.
Recent Funding Rounds With recent funding of $30.6 million and initial public offering in 2021, Corvus Pharmaceuticals shows financial stability, indicating a potential for partnership or investment opportunities for companies in the biotech and pharmaceutical sectors.
Key Personnel Additions The appointment of key executives like Jeffrey Arcara and James Rosenbaum as Chief Business Officer and Senior Vice President of Research, respectively, signifies a strategic growth phase, presenting a chance for collaborations on research and development projects.
Clinical Data Updates Corvus regularly updates its clinical data on drugs like CPI-818, enhancing credibility in the medical community and offering a chance for discussions with healthcare professionals interested in emerging treatments.
Market Positioning Being a clinical-stage biopharmaceutical company with a revenue range of $10M - $50M, Corvus presents itself as a competitive player in the market, inviting discussions around potential partnerships or distribution agreements.
$10M$50M
$10M$50M
$50M$100M
$50M$100M
$50M$100MCorvus Pharmaceuticals uses 8 technology products and services including Google Analytics, Microsoft PowerPoint, Backbone.js, and more. Explore Corvus Pharmaceuticals's tech stack below.
| Corvus Pharmaceuticals Email Formats | Percentage |
| FLast@corvuspharma.com | 92% |
| Last@corvuspharma.com | 5% |
| Last_First@corvuspharma.com | 2% |
| FMLast@corvuspharma.com | 1% |
Biotechnology ResearchCalifornia, United States51-200 Employees
Corvus is a unique environment for exceptional individuals who want to learn, contribute to an exceptional team, and make a difference in the lives of people with cancer. At Corvus, we take pride in our collaborative, community-based culture. We understand that the most successful teams are those that learn from each other and co-create in an environment that nurtures open, transparent communication.
Company Overview
Media & News
Funding & FinancialsCorvus Pharmaceuticals has raised a total of $31M of funding over 6 rounds. Their latest funding round was raised on May 02, 2024 in the amount of $31M.
Corvus Pharmaceuticals's revenue is in the range of $10M$50M
Funding & FinancialsCorvus Pharmaceuticals has raised a total of $31M of funding over 6 rounds. Their latest funding round was raised on May 02, 2024 in the amount of $31M.
Corvus Pharmaceuticals's revenue is in the range of $10M$50M
1-888-653-2347 
support@leadiq.com